Abstract Number: 1286 • ACR Convergence 2020
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus by Physician Global Assessment of Disease Activity
Background/Purpose: The risk of cardiovascular disease (CVD), including myocardial infarction and stroke, is higher in SLE than in the general population. The excess risk of…Abstract Number: 1302 • ACR Convergence 2020
Exploration of Machine Learning Methods in Predicting Systemic Lupus Erythematosus Hospitalizations
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease associated with increased morbidity and mortality, and severe SLE flares can lead to hospitalizations. Our objective…Abstract Number: 1512 • ACR Convergence 2020
Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis
Background/Purpose: . Pure membranous (class V) lupus nephritis is considered a less aggressive phenotype, but renal fibrosis and chronic kidney disease may develop. Whether this…Abstract Number: 1671 • ACR Convergence 2020
Identifying Rare Genetic Variants in Childhood-onset Monogenic Systemic Lupus Erythematosus
Background/Purpose: Among children diagnosed with systemic lupus erythematosus (SLE), there exists monogenic forms of SLE, where rare variants in a single gene lead to disease.…Abstract Number: 1773 • ACR Convergence 2020
Worse Maternal and Fetal Outcomes Among Hospitalized U.S. Pregnant Women with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)
Background/Purpose: Prior studies suggest women with SLE and RA may have higher age-adjusted risk of adverse pregnancy outcomes. We evaluated maternal and fetal complications and…Abstract Number: 1800 • ACR Convergence 2020
Association of Air Pollution with Systemic Lupus Erythematosus Disease Activity in the Central Valley of California
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex multisystem autoimmune disease that affects at least 300,000 people in the United States creating a substantial socioeconomic…Abstract Number: 1818 • ACR Convergence 2020
IgG and IgA Autoantibodies Against L1 ORF1p Expressed in Granulocytes Correlate with Granulocyte Consumption and Disease Activity in Pediatric Systemic Lupus Erythematosus
Background/Purpose: To quantitate autoantibodies against the RNA-binding p40 (ORF1p) protein encoded by the L1 retroelement, expression of p40 itself, and markers of neutrophil death in…Abstract Number: 1834 • ACR Convergence 2020
Biomarker Analysis of IFN-I Modulation in JNJ-839: First-in-Human Study for Systemic Lupus Erythematosus
Background/Purpose: JNJ-839 is a fully human neutralizing antibody selective to human IFN-ω and IFN-α subtypes. Here we report the exploratory biomarker analyses of a Phase…Abstract Number: 1986 • ACR Convergence 2020
Determinants of Variation in Pediatric Systemic Lupus Erythematosus Care Delivery
Background/Purpose: Patients with pediatric systemic lupus erythematosus (pSLE) receive only a fraction of recommended care. Moreover, variation in care delivery likely contributes to pervasive racial…Abstract Number: 0045 • ACR Convergence 2020
Healthcare Practitioner Confidence Assessing Rashes in Patients of Skin of Color with Lupus
Background/Purpose: Medical education can promote bias that disproportionately affects patients of color. Patients of color with lupus are especially vulnerable as they often carry a…Abstract Number: 0255 • ACR Convergence 2020
Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational Definition of the Lupus Low Disease Activity State – Implications for Use as a Trial Endpoint
Background/Purpose: The Lupus Low Disease Activity State (LLDAS) has recently undergone prospective longitudinal validation in a multinational cohort, demonstrating the association of attaining LLDAS with…Abstract Number: 0272 • ACR Convergence 2020
Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold
Background/Purpose: Treat-to-target (T2T) approaches to rheumatic disease require the definition and validation of low disease activity and remission endpoints that should be concentrically more stringent.…Abstract Number: 0290 • ACR Convergence 2020
Role of Protein Tyrosine Phosphatase 1B (PTP1B) in Endothelial-to-Mesenchymal Transition (EndoMT) Promoted by Inflammation: Implications for SLE
Background/Purpose: The endothelial-to-mesenchymal transition (EndoMT) transdifferentiation process can be promoted by several proinflammatory mediators in many pathological conditions. Recently, it was suggested a crucial role…Abstract Number: 0431 • ACR Convergence 2020
Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis…Abstract Number: 0529 • ACR Convergence 2020
A Prospective Study on the Incidence of a First Thrombo-embolic Event in Patients with Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies
Background/Purpose: Prospective data confirming the role of anti-phosphatidylserine/prothrombin antibodies (aPS/PT) in the absence of other aPL tested by β2–glycoprotein I-depend assays are missing.Methods: Since 2015 aPSPT…
- « Previous Page
- 1
- …
- 120
- 121
- 122
- 123
- 124
- …
- 150
- Next Page »